ADA Scientific Sessions 2026 Abstract

Exploring a Lower Starting Dose of Aleniglipron, an Oral Small Molecule GLP-1RA, to Improve GI Tolerability in Obesity: Beyond the ACCESS Trials

By Timothy Richard Smith, Andres J Acosta, Kevin Cannon, Blai Coll

Trial in peopleInterventions

The paper

Timothy Richard Smith, Andres J Acosta, Kevin Cannon, Blai Coll

St Peters

ADA Scientific Sessions 2026 Abstract, 5 Jun 2026

Presented at ADA Scientific Sessions 2026, late-breaking 3101-LB

doi.org/10.2337/db26-3101-lb

Lancet4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
Lancet4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
The New England Journal of Medicine4 Oct 2026
Retatrutide reduces weight and pain in adults with obesity